High-dose semaglutide and how fast the stomach empties in people with obesity
Tests how semaglutide affects stomach emptying in adults with obesity.
Plain-language title generated from the registry record
Registry title: A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight
Key facts
- Where
- Graz, AustriaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity (BMI 30.0 to 44.9). It studies how semaglutide affects emptying of the stomach.
- Age
- 18 to 64 years
- Sex
- Men and women (sex assigned at birth, all gender identities)
- Disease stage
- Obesity due to excess body fat, with a body mass index (BMI) between 30.0 and 44.9 kg/m^2 at screening
- Earlier treatment
- No prescription or non-prescription medicines, including herbal medicines such as St. John's Wort, that interfere with the CYP pathways within 14 days (or 5 half-lives, whichever is longest) of screening. Routine vitamins and occasional paracetamol, ibuprofen or acetylsalicylic acid are allowed.
Main reasons for not taking part
- Known or suspected allergy to the study medicines, including paracetamol
- Use of medicines or herbal products that interfere with the CYP pathways within 14 days of screening
- Poor liver function: ALT or AST at least 2.5 times the upper limit of normal
- Poor liver function: total bilirubin more than 1.5 times the upper limit of normal
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Source: NCT07845578, who can take part
Where in Austria
- Medical University of GrazGraz, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07845578EU 2026-526083-20-00
- Record updated
- 29 September 2026
- Original description
The purpose of the study is to determine the effect of semaglutide on gastric emptying in people with obesity. Participants will receive either semaglutide or placebo, and the treatment assigned will be decided by chance. Semaglutide is a medicine that doctors can already prescribe, while placebo contains no active medicine.Read full original descriptionShow less
An Investigation of the Effect of High Dose s.c. Semaglutide on Gastric Emptying in Participants With Obesity
The purpose of the study is to determine the effect of semaglutide on gastric emptying in people with obesity. Participants will receive either semaglutide or placebo, and the treatment assigned will be decided by chance. Semaglutide is a medicine that doctors can already prescribe, while placebo contains no active medicine.
Inclusion: Age 18-64 years (both inclusive) at the time of signing the informed consent; Male or female (sex assigned at birth, inclusive of all gender identities); Body mass index (BMI) between 30.0 - 44.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening. Obesity should be due to excess adipose tissue, as judged by the investigator.
Exclusion: Use of prescription medicinal products or non-prescription drugs, including any herbal medicine known to interfere with the metabolic CYP pathways, such as perikon (St. John's Wort), within 14 days (or within 5 half-lives of the medicinal product, whichever is longest) of screening, with the exception of use of routine vitamins (vitamins used within a normal dose reference interval) and occasional use of paracetamol/acetaminophen, ibuprofen and acetylsalicylic acid, or topical medication not reaching systemic circulation; Known or suspected hypersensitivity to study intervention(s) (including paracetamol) or related products; Impaired liver function defined as any of the below:; Alanine Aminotransferase (ALT) greater than or equal to (>= ) 2.5 times the upper limit of normal (ULN); Aspartate Aminotransferase (AST) >=2.5 times ULN; Total bilirubin greater than (>) 1.5 times ULN.